Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

@article{Rizvi2011MolecularCP,
  title={Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.},
  author={Naiyer A Rizvi and Valerie M Rusch and William Pao and Jamie E Chaft and Marc Ladanyi and Vincent A. Miller and Lee Krug and Christopher Azzoli and Manjit Bains and Robert S. Downey and Raja Flores and Bernard J H Park and Bhuvanesh Singh and Maureen F. Zakowski and Robert T. Heelan and Ronglai Shen and Mark G. Kris},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 10},
  pages={3500-6}
}
PURPOSE To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). PATIENTS AND METHODS Patients with resectable stage I and II non-small cell lung cancer (NSCLC) enriched for the likelihood of EGFR mutation (≤ 15 pack-year cigarette smoking history… CONTINUE READING